{
  "ticker": "EVE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970984",
  "id": "02970984",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250721",
  "time": "0927",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250721/pdf/06lzg8j0lsf5ry.pdf",
  "summary": "- **Regulatory approval secured** for Libbo (ED) and Dyspro (dysmenorrhoea) under TGA pathways, enabling Australian prescription access.  \n- **Commercial launch expected by end of 2025**, ahead of original timeline.  \n- **First purchase order submitted** for Dyspro, with prescriber coverage via telehealth/GP clinics.  \n- **Export submissions planned** post-launch to support global expansion.  \n- **Product stability**: Libbo (2-year expiry), Dyspro (1-year expiry), with ongoing GMP testing.  \n\n*No material trading or capital markets actions (e.g., capital raising, liquidity events) identified.*",
  "usage": {
    "prompt_tokens": 992,
    "completion_tokens": 138,
    "total_tokens": 1130,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-20T23:43:20.857897"
}